紫杉醇联合或不联合帕唑帕尼治疗贝伐珠单抗维持治疗期间复发的卵巢癌:GINECO随机II期TAPAZ研究
在贝伐珠单抗维持治疗第一年内复发的卵巢癌患者中,随机2:1接受每周紫杉醇65 mg/m2联合帕唑帕尼600-800 mg每日或标准每周紫杉醇80 mg/m2。联合组与单药组的4个月无进展生存率分别为61%和68%,无差异;联合组3/4级毒性更高(87% vs 70%)。结论:加用帕唑帕尼未改善疗效、增加毒性并影响化疗实施。
要点
- 联合组与单药组4个月PFS率分别为61%和68%,无差异。
- 联合组3/4级毒性发生率为87%,高于单药组的70%。
- 联合组因毒性停用帕唑帕尼者占44%,发生两例治疗相关死亡。
核心结论
- 在贝伐珠单抗维持治疗期间进展的复发性卵巢癌中,紫杉醇加用帕唑帕尼未改善疗效、增加毒性并影响化疗实施。
研究设计与样本
- 随机II期TAPAZ研究纳入贝伐珠单抗维持治疗第一年内复发的卵巢癌患者,按2:1随机分配至每周紫杉醇65 mg/m2联合帕唑帕尼600-800 mg每日组或标准每周紫杉醇80 mg/m2组,共116例接受治疗(联合组79例,单药组37例),主要终点为4个月无进展生存率。
主要发现
- 联合组与单药组的4个月PFS率分别为61%(95%CI 51-73%)和68%(95%CI 54-85%),无差异。
- 联合组与单药组的中位PFS分别为4.9个月(95%CI 4.1-6.1)和5.8个月(95%CI 4.8-7.4),中位总生存分别为13.6个月和12.9个月。
- 联合组与单药组的3/4级毒性发生率分别为87%和70%,因毒性停用紫杉醇的比例分别为22%和11%。
- 联合组44%的患者因毒性停用帕唑帕尼,最常见为胃肠道和血管事件;两例治疗相关死亡均发生在联合组(肺栓塞和胃肠道穿孔)。
- 第4个月时联合组患者报告结局较基线恶化,尤其是腹部/胃肠道症状,与单药组相比有临床重要差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab. METHODS: In the randomized phase II TAPAZ trial, patients with rOC during the first year of bevacizumab maintenance therapy were assigned 2:1 to either weekly paclitaxel 65 mg/m2 plus pazopanib 600-800 mg daily or standard weekly paclitaxel 80 mg/m2. The primary endpoint was 4-month progression-free survival (PFS) rate. RESULTS: Overall, 116 patients were randomized and treated: 79 with combination therapy and 37 with single-agent paclitaxel. Median follow-up was 13.1 months. There was no difference between treatment arms in 4-month PFS rate (61% [95% CI, 51-73%] with the combination versus 68% [95% CI, 54-85%] with paclitaxel alone), median PFS (4.9 [95% CI, 4.1-6.1] versus 5.8 [95% CI, 4.8-7.4] months, respectively) or median overall survival (13.6 versus 12.9 months, respectively). The combination was associated with more grade 3/4 toxicities (87% versus 70%, respectively) and toxicity-related paclitaxel discontinuations (22% versus 11%). Pazopanib was discontinued for toxicity in 44% of patients, most commonly for gastrointestinal and vascular events. There were two treatment-related deaths, both in the combination arm (pulmonary embolism and gastrointestinal perforation). At month 4, patient-reported outcomes deteriorated from baseline in the combination arm, particularly for abdominal/gastrointestinal symptoms, which showed a clinically important difference versus paclitaxel alone. CONCLUSIONS: In rOC progressing during maintenance bevacizumab, adding pazopanib to paclitaxel did not improve efficacy, increased toxicity, and compromised chemotherapy delivery. CLINICALTRIALS: govregistration:NCT02383251.
引用
- Joly F, Fabbro M, Berton D, et al. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study. Gynecol Oncol. 2022. PMID: 35902297. doi:10.1016/j.ygyno.2022.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。